Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, 1730 W 25th Street, Cleveland, OH 44113, United States.
Middlebury College, Middlebury, VT, United States.
Int J Drug Policy. 2022 Jan;99:103473. doi: 10.1016/j.drugpo.2021.103473. Epub 2021 Oct 6.
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries such as Australia, Canada, Israel, New Zealand, and the United Kingdom have begun supporting it. Given that the United States National Institutes of Health (NIH) is the largest public funder of biomedical research in the world, it is important to understand the degree to which the organization is supporting clinical trials of psychedelic-assisted therapies. We are unaware of existing literature quantifying direct NIH grant support for psychedelic-assisted therapy clinical trials, so we sought to answer this important question by searching all NIH grants awarded since the beginning of the psychedelic renaissance.
We queried NIH RePORTER, NIH's grant database, for grants awarded from 2006-2020 mentioning the psychedelics 3,4-Methylenedioxymethamphetamine (MDMA), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ayahuasca, dimethyltryptamine (DMT), ibogaine, lysergic acid (LSD), mescaline, peyote, and psilocybin. We manually reviewed resulting grants to determine whether they directly funded psychedelic-assisted therapy clinical trials.
We identified zero NIH grants directly funding psychedelic-assisted therapy clinical trials during the study period.
While governmental biomedical research funding bodies in other countries have begun funding clinical trials of psychedelic-assisted therapies during the psychedelic renaissance, NIH has yet to directly fund a single psychedelic-assisted therapy clinical trial. Concerns about risks related to psychedelics, a federal law preventing promotion of legalization of Schedule 1 drugs, and prioritization of grants for other types of studies on psychedelics may explain the dearth of NIH funding for psychedelic-assisted therapy clinical trials.
许多人表示，医学目前正在经历一场“迷幻复兴”，这场复兴始于 2006 年。从那时起，临床试验一直为迷幻辅助疗法在治疗各种心理健康状况和成瘾方面的应用提供了有希望的结果。虽然这项工作大多是由私人资助的，但澳大利亚、加拿大、以色列、新西兰和英国等国家的政府生物医学研究资助机构已经开始支持这项工作。鉴于美国国立卫生研究院（NIH）是世界上最大的生物医学研究公共资助者，了解该组织在多大程度上支持迷幻辅助疗法的临床试验非常重要。我们不知道现有的文献是否有量化 NIH 直接资助迷幻辅助治疗临床试验的内容，因此，我们通过搜索自迷幻复兴开始以来 NIH 授予的所有研究基金，试图回答这个重要的问题。
我们通过 NIH 的资助数据库 RePORTER 查询了 NIH 从 2006 年至 2020 年期间授予的研究基金，这些基金提到了迷幻剂 3,4-亚甲二氧基甲基苯丙胺（MDMA）、5-甲氧基-N,N-二甲基色胺（5-MeO-DMT）、卡瓦胡椒、二甲色胺（DMT）、伊博加因、麦角酸（LSD）、三甲氧苯乙胺、佩奥特掌和裸盖菇素。我们手动审查了这些研究基金，以确定它们是否直接资助了迷幻辅助治疗的临床试验。
在研究期间，我们没有发现 NIH 直接资助迷幻辅助治疗临床试验的研究基金。
虽然其他国家的政府生物医学研究资助机构在迷幻复兴期间已经开始资助迷幻辅助疗法的临床试验，但 NIH 尚未直接资助一项迷幻辅助治疗的临床试验。对迷幻剂相关风险的担忧、一项禁止推广附表 1 药物合法化的联邦法律，以及对其他类型迷幻剂研究的资助优先排序，可能解释了 NIH 对迷幻辅助治疗临床试验资金匮乏的原因。
